<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cachexia Sarcopenia Muscle</journal-id><journal-id journal-id-type="iso-abbrev">J Cachexia Sarcopenia Muscle</journal-id><journal-id journal-id-type="doi">10.1007/13539.2190-6009</journal-id><journal-id journal-id-type="publisher-id">JCSM</journal-id><journal-title-group><journal-title>Journal of Cachexia, Sarcopenia and Muscle</journal-title></journal-title-group><issn pub-type="ppub">2190-5991</issn><issn pub-type="epub">2190-6009</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28891198</article-id><article-id pub-id-type="pmc">5803606</article-id><article-id pub-id-type="doi">10.1002/jcsm.12228</article-id><article-id pub-id-type="publisher-id">JCSM12228</article-id><article-id pub-id-type="other">JCSM-D-17-00032</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial</article-title><alt-title alt-title-type="right-running-head">Cachexia in COPD: TMN RCT</alt-title><alt-title alt-title-type="left-running-head">P.C. Calder <italic>et al.</italic></alt-title></title-group><contrib-group><contrib id="jcsm12228-cr-0001" contrib-type="author" corresp="yes"><name><surname>Calder</surname><given-names>Philip C.</given-names></name><address><email>p.c.calder@soton.ac.uk</email></address><xref ref-type="aff" rid="jcsm12228-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jcsm12228-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcsm12228-cr-0002" contrib-type="author"><name><surname>Laviano</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="jcsm12228-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcsm12228-cr-0003" contrib-type="author"><name><surname>Lonnqvist</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="jcsm12228-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jcsm12228-cr-0004" contrib-type="author"><name><surname>Muscaritoli</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="jcsm12228-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcsm12228-cr-0005" contrib-type="author"><name><surname>&#x000d6;hlander</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="jcsm12228-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jcsm12228-cr-0006" contrib-type="author"><name><surname>Schols</surname><given-names>Annemie</given-names></name><xref ref-type="aff" rid="jcsm12228-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="jcsm12228-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Human Development and Health Academic Unit, Faculty of Medicine</named-content>
<institution>University of Southampton</institution>
<named-content content-type="street">Tremona Road, SO16 6YD</named-content>
<named-content content-type="city">Southampton</named-content>
<country country="GB">UK</country>
</aff><aff id="jcsm12228-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">NIHR Southampton Biomedical Research Centre</named-content>
<institution>University Hospital Southampton NHS Foundation Trust and University of Southampton</institution>
<named-content content-type="street">Tremona Road, SO16 6YD</named-content>
<named-content content-type="city">Southampton</named-content>
<country country="GB">UK</country>
</aff><aff id="jcsm12228-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<institution>Sapienza University of Rome</institution>
<named-content content-type="city">Rome</named-content>
<country country="IT">Italy</country>
</aff><aff id="jcsm12228-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Molecular Medicine and Surgery and the Center for Molecular Medicine</named-content>
<institution>Karolinska Institute</institution>
<named-content content-type="city">Stockholm</named-content>
<country country="SE">Sweden</country>
</aff><aff id="jcsm12228-aff-0005" content-type="private-address">
<label><sup>5</sup></label>
<institution>Smartfish AS</institution>
<named-content content-type="city">Oslo</named-content>
<country country="NO">Norway</country>
</aff><aff id="jcsm12228-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism</named-content>
<institution>Maastricht University Medical Centre</institution>
<named-content content-type="city">Maastricht</named-content>
<country country="NL">Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence to: Professor Philip C. Calder, Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, IDS Building, MP887 Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. Email:<email>p.c.calder@soton.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><volume>9</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/jcsm.v9.1</issue-id><fpage>28</fpage><lpage>40</lpage><history><date date-type="received"><day>15</day><month>2</month><year>2017</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 The Authors. Published by John Wiley & Sons Ltd. on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley &#x00026; Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCSM-9-28.pdf"/><abstract><title>Abstract</title><sec id="jcsm12228-sec-0001"><title>Background</title><p>Cachectic patients with chronic obstructive pulmonary disease (COPD) may benefit from nutritional support. This double&#x02010;blind, randomized, controlled trial evaluated the safety and efficacy of targeted medical nutrition (TMN) vs. an isocaloric comparator in pre&#x02010;cachectic and cachectic patients with COPD.</p></sec><sec id="jcsm12228-sec-0002"><title>Methods</title><p>Patients aged &#x02265;50&#x000a0;years with moderate&#x02010;to&#x02010;severe COPD and involuntary weight loss or low body mass index (16&#x02013;18&#x000a0;kg/m<sup>2</sup>) were randomized 1:1 to receive TMN (~230&#x000a0;kcal; 2&#x000a0;g omega&#x02010;3 fatty acids; 10&#x000a0;&#x003bc;g 25&#x02010;hydroxy&#x02010;vitamin D3) or isocaloric comparator twice daily for 12&#x000a0;weeks (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT02442908). Primary safety endpoints comprised adverse events and changes in vital signs, laboratory parameters, and concomitant medications. Secondary efficacy endpoints included changes in weight, body composition, exercise tolerance, metabolic biomarkers, and systemic inflammation.</p></sec><sec id="jcsm12228-sec-0003"><title>Results</title><p>Forty&#x02010;five patients were randomized to receive TMN (<styled-content style="italic-in-any-context">n</styled-content>&#x000a0;=&#x000a0;22; mean 69.2&#x000a0;years) or isocaloric comparator (<styled-content style="italic-in-any-context">n</styled-content>&#x000a0;=&#x000a0;23; mean 69.7&#x000a0;years). TMN was well tolerated. Adverse events were similar in number and type in both groups. Compliance to both products was good (TMN, 79%; comparator, 77%). Both groups gained weight, but the TMN group gained comparatively more fat mass (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0013). Reductions in systolic blood pressure (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0418) and secondary endpoints of triglycerides (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0217) and exercise&#x02010;induced fatigue (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0223) and dyspnoea (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0382), and increases in high&#x02010;density lipoprotein cholesterol (<styled-content style="italic-in-any-context">P</styled-content>&#x000a0;=&#x000a0;0.0254), were observed in the TMN vs. the comparator group by week 12.</p></sec><sec id="jcsm12228-sec-0004"><title>Conclusions</title><p>Targeted medical nutrition containing high&#x02010;dose omega&#x02010;3 fatty acids, vitamin D, and high&#x02010;quality protein is well tolerated with a good safety profile and has positive effects on blood pressure and blood lipids and on exercise&#x02010;induced fatigue and dyspnoea. Therefore, this TMN could be clinically beneficial in the nutritional and metabolic support of pre&#x02010;cachectic and cachectic patients with COPD.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcsm12228-kwd-0001">Cachexia</kwd><kwd id="jcsm12228-kwd-0002">Chronic obstructive pulmonary disease</kwd><kwd id="jcsm12228-kwd-0003">Nutrition</kwd><kwd id="jcsm12228-kwd-0004">Omega&#x02010;3 fatty acids</kwd><kwd id="jcsm12228-kwd-0005">Pre&#x02010;cachexia</kwd></kwd-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="13"/><word-count count="4254"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jcsm12228</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:08.02.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcsm12228-cit-0000">
<string-name>
<surname>Calder</surname>, <given-names>P. C.</given-names>
</string-name>, <string-name>
<surname>Laviano</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lonnqvist</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Muscaritoli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>&#x000d6;hlander</surname>, <given-names>M.</given-names>
</string-name>, and <string-name>
<surname>Schols</surname>, <given-names>A.</given-names>
</string-name> (<year>2018</year>) <article-title>Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial</article-title>. <source>Journal of Cachexia, Sarcopenia and Muscle</source>, <volume>9</volume>: <fpage>28</fpage>&#x02013;<lpage>40</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/jcsm.12228">10.1002/jcsm.12228</ext-link>.</mixed-citation>
</p></notes></front><body><sec id="jcsm12228-sec-0005"><title>Introduction</title><p>Cachexia is a complex syndrome frequently present in patients with chronic obstructive pulmonary disease (COPD) and other chronic illnesses including cancer<xref rid="jcsm12228-bib-0001" ref-type="ref">1</xref> and congestive heart failure.<xref rid="jcsm12228-bib-0002" ref-type="ref">2</xref> Cachexia is associated with increased mortality,<xref rid="jcsm12228-bib-0003" ref-type="ref">3</xref> impairments in health&#x02010;related quality of life (HRQoL), and muscle weakness.<xref rid="jcsm12228-bib-0004" ref-type="ref">4</xref>, <xref rid="jcsm12228-bib-0005" ref-type="ref">5</xref> The clinical phenotype of cachexia ranges from minimal or no weight loss, with signs of muscle wasting (e.g. anorexia, inflammation) to severe weight loss, muscle depletion, fatigue, and reduced mobility.</p><p>In patients with COPD, early multimodal intervention, including nutritional support, has clinical benefits, both in patients with overt cachexia and in those with minimal or no weight loss (&#x02018;pre&#x02010;cachexia&#x02019;).<xref rid="jcsm12228-bib-0006" ref-type="ref">6</xref> Meta&#x02010;analyses of randomized controlled trials (RCTs) have demonstrated the benefits of nutritional interventions on body weight, fat&#x02010;free mass index, exercise tolerance, and respiratory and non&#x02010;respiratory muscle strength in patients with COPD.<xref rid="jcsm12228-bib-0007" ref-type="ref">7</xref>, <xref rid="jcsm12228-bib-0008" ref-type="ref">8</xref> Limited evidence also suggests that body composition and exercise capacity may be improved, and inflammatory activity reduced, by nutritional interventions containing high doses of omega&#x02010;3 polyunsaturated fatty acids (PUFAs). In an 8&#x02010;week RCT in 80 patients with COPD, daily supplementation with a PUFA blend including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha&#x02010;linolenic acid significantly improved exercise capacity compared with placebo.<xref rid="jcsm12228-bib-0009" ref-type="ref">9</xref> In another RCT, daily supplementation with omega&#x02010;3 PUFAs alongside low&#x02010;intensity exercise for 12&#x000a0;weeks produced clear benefits compared with standard care in 32 clinically stable, malnourished patients with moderate&#x02010;to&#x02010;severe COPD<xref rid="jcsm12228-bib-0010" ref-type="ref">10</xref>; the intervention significantly increased energy intake, improved body composition, and reduced levels of the inflammatory biomarkers, C&#x02010;reactive protein, interleukin (IL)&#x02010;6, IL&#x02010;8, and tumour necrosis factor. The results from these RCTs are noteworthy given that in a separate study, non&#x02010;responders to a high&#x02010;calorie nutritional supplement had higher inflammatory biomarker levels than those who gained weight.<xref rid="jcsm12228-bib-0011" ref-type="ref">11</xref>
</p><p>There is also an evidence&#x02010;based rationale for patients with COPD taking other nutrients including vitamin D<xref rid="jcsm12228-bib-0012" ref-type="ref">12</xref> and some dietary antioxidants including plant polyphenols.<xref rid="jcsm12228-bib-0013" ref-type="ref">13</xref> Furthermore, high&#x02010;quality protein is acknowledged to be important for optimal skeletal muscle protein synthesis.<xref rid="jcsm12228-bib-0014" ref-type="ref">14</xref>
</p><p>To date, few RCTs of nutritional support for patients with COPD have included appropriate controls. This trial is the first RCT of its kind to compare the safety and efficacy of supplementation with a complex targeted medical nutrition (TMN) formulation containing high&#x02010;dose omega&#x02010;3 PUFAs, 25&#x02010;hydroxy&#x02010;vitamin D3, plant antioxidants, and high&#x02010;quality whey protein with an isocaloric comparator matched for energy content, in pre&#x02010;cachectic and cachectic patients with COPD. This trial primarily aimed to assess safety and tolerability; secondary objectives were to evaluate the efficacy of TMN in improving measures of clinical relevance in COPD, including body composition, inflammation, muscle function, and HRQoL.</p></sec><sec id="jcsm12228-sec-0006"><title>Methods</title><sec id="jcsm12228-sec-0007"><title>Study design</title><p>This 12&#x02010;week randomized, parallel group, double&#x02010;blind, placebo&#x02010;controlled, multicentre trial assessed the safety and tolerability of TMN (Nutrifriend Cachexia; Smartfish, Oslo, Norway) in patients with COPD (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT02442908). Patients at five sites in Sweden (Ladulaas Kliniska Studier, Bor&#x000e5;s; Pharmasite, Helsingborg; Pharmasite, Malm&#x000f6;; A+ Science City Site, Stockholm; Probare, Lund) were randomized 1:1 to receive TMN or isocaloric comparator. It was determined a priori that 25 evaluable patients per group would be sufficient to meet the primary objective; thus, no formal power calculation was made.</p><p>The study was conducted in accordance with good clinical practice and the Declaration of Helsinki. All patients provided written informed consent. The study protocol and amendment were reviewed and approved by the Regional Ethics Committee in Gothenburg, Sweden.</p></sec><sec id="jcsm12228-sec-0008"><title>Participants</title><p>Eligible participants were patients aged &#x02265;50&#x000a0;years with moderate&#x02010;to&#x02010;severe COPD [based on forced expiratory volume in 1&#x000a0;s (FEV<sub>1</sub>) 30&#x02013;60% of predicted value, post&#x02010;bronchodilator] and involuntary weight loss in the 12&#x000a0;months before randomization [&#x02264;10% for body mass index (BMI) of 18&#x02013;32&#x000a0;kg/m<sup>2</sup>] or a low BMI (16&#x02013;18&#x000a0;kg/m<sup>2</sup>) without weight loss, and adequate hepatic and renal function. A 5% weight loss threshold was used to distinguish between overt vs. pre&#x02010;cachexia, as per the European Society for Clinical Nutrition and Metabolism's consensus definitions<xref rid="jcsm12228-bib-0015" ref-type="ref">15</xref>; cachexia was defined as 5&#x02013;10% weight loss and pre&#x02010;cachexia as low BMI or &#x02264;5% weight loss over the 12&#x000a0;months before randomization. Classification according to European Respiratory Society's definition(s) of pre&#x02010;cachexia (unintentional weight loss of &#x0003e;5%) and cachexia [unintentional weight loss of &#x0003e;5% with fat&#x02010;free mass index of &#x0003c;17&#x000a0;kg/m<sup>2</sup> (for men) or &#x0003c;15&#x000a0;kg/m<sup>2</sup> (for women), as determined by dual&#x02010;energy X&#x02010;ray absorptiometry] was also assessed.<xref rid="jcsm12228-bib-0016" ref-type="ref">16</xref> Exclusion criteria included having received &#x0003e;5&#x000a0;mg/day oral corticosteroids, anabolic steroids, or nutritional supplements containing EPA/DHA within 3&#x000a0;months prior to screening. Patients experiencing COPD exacerbations or major changes in COPD maintenance treatment within 3&#x000a0;months prior to screening were also excluded (refer to Table&#x000a0;<xref rid="jcsm12228-supitem-0001" ref-type="supplementary-material">S1</xref> for full inclusion/exclusion criteria). During the study, products containing omega&#x02010;3 PUFAs, oral steroids &#x0003e;5&#x000a0;mg/day (unless as treatment for ongoing COPD exacerbation), and nutritional supplements that the investigator considered could influence safety and efficacy outcomes were restricted.</p></sec><sec id="jcsm12228-sec-0009"><title>Nutritional intervention</title><p>Patients were randomized at baseline to receive TMN (approximately 230&#x000a0;kcal; 10&#x000a0;g whey protein concentrate, minimum 2.0&#x000a0;g DHA&#x000a0;+&#x000a0;EPA, and 10&#x000a0;&#x003bc;g 25&#x02010;hydroxy&#x02010;vitamin D3 per 200&#x000a0;mL) or a milk&#x02010;based comparator that contained no 25&#x02010;hydroxy&#x02010;vitamin D3, milk protein instead of pure whey protein, and sunflower oil in place of omega&#x02010;3 PUFA&#x02010;containing fish oil (approximately 200&#x000a0;kcal per 200&#x000a0;mL). Doses of TMN components were chosen based on published data on omega&#x02010;3 PUFA&#x02010;containing supplements and other medical nutrition products from Smartfish.<xref rid="jcsm12228-bib-0017" ref-type="ref">17</xref>, <xref rid="jcsm12228-bib-0018" ref-type="ref">18</xref>, <xref rid="jcsm12228-bib-0019" ref-type="ref">19</xref>, <xref rid="jcsm12228-bib-0020" ref-type="ref">20</xref> Trial Form Support, AB (Lund, Sweden) implemented randomization by assigning patients a three&#x02010;digit number allocating them to a treatment group; patients at each site were assigned numbers sequentially. Access to randomization details was restricted until study end.</p><p>Patients were instructed to drink two 200&#x000a0;mL study product containers daily for 12&#x000a0;weeks. Labelling conformed to local regulations and ensured that the contents were not identifiable. Patients received dietary and exercise advice at screening and were required to report changes in smoking habits or diet, with the exception of increasing caloric intake if appetite increased. They were assessed at screening (days &#x02212;14 to &#x02212;1), baseline (day 1), and every 3&#x000a0;weeks thereafter (weeks 3&#x02013;12). Patients were followed up by telephone on weeks 3 and 9; all other assessments were face&#x02010;to&#x02010;face. No COPD inhalation treatment was permitted on the mornings of screening, baseline, and final assessment; patients fasted after 22:00&#x000a0;h the night before face&#x02010;to&#x02010;face assessments after screening.</p></sec><sec id="jcsm12228-sec-0010"><title>Outcome measures</title><p>
<italic>Table</italic>
<xref rid="jcsm12228-tbl-0001" ref-type="table-wrap">1</xref> gives details of all study endpoints and how they were measured.<xref rid="jcsm12228-bib-0021" ref-type="ref">21</xref>, <xref rid="jcsm12228-bib-0022" ref-type="ref">22</xref>, <xref rid="jcsm12228-bib-0023" ref-type="ref">23</xref>, <xref rid="jcsm12228-bib-0024" ref-type="ref">24</xref>, <xref rid="jcsm12228-bib-0025" ref-type="ref">25</xref>, <xref rid="jcsm12228-bib-0026" ref-type="ref">26</xref> Primary safety endpoints comprised number and type of adverse events (AEs) over 12&#x000a0;weeks and change from baseline to week 12 in vital signs, laboratory safety parameters, and concomitant medications.</p><table-wrap id="jcsm12228-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Measurement of primary, secondary, and exploratory study endpoints</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Endpoint</th><th align="center" style="padding-left:15%" valign="bottom" rowspan="1" colspan="1">Measurement</th><th align="center" style="padding-left:15%" valign="bottom" rowspan="1" colspan="1">Time point</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1">Primary safety endpoints</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse events</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0001"><list-item id="jcsm12228-li-0001"><p>Any untoward medical occurrence in a patient who received a study product, which does not necessarily have a causal relationship with the treatment.</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0002"><list-item id="jcsm12228-li-0002"><p>Throughout the study period</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Physical examination</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0003"><list-item id="jcsm12228-li-0003"><p>Examination of cardiovascular system, respiratory system, abdomen, skin, and nervous system</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0004"><list-item id="jcsm12228-li-0004"><p>Screening, baseline, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vital signs</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0005"><list-item id="jcsm12228-li-0005"><p>Resting systolic and diastolic blood pressure and heart rate</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0006"><list-item id="jcsm12228-li-0006"><p>Screening, baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Laboratory safety measures</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0007"><list-item id="jcsm12228-li-0007"><p>Blood haemoglobin level, platelet and haematocrit counts, complete blood count, and white blood cell differential count</p></list-item><list-item id="jcsm12228-li-0008"><p>Serum creatinine, bilirubin, ALP, ALT, AST, potassium, and sodium levels</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0008"><list-item id="jcsm12228-li-0009"><p>Screening, baseline, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other safety measures</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0009"><list-item id="jcsm12228-li-0010"><p>Changes in concomitant medication</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0010"><list-item id="jcsm12228-li-0011"><p>Screening, baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Secondary efficacy endpoints</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Weight and body measurements</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0011"><list-item id="jcsm12228-li-0012"><p>Weight</p></list-item><list-item id="jcsm12228-li-0013"><p>Height</p></list-item><list-item id="jcsm12228-li-0014"><p>Waist and calf circumference</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0012"><list-item id="jcsm12228-li-0015"><p>Screening, baseline, week 6, and week 12</p></list-item><list-item id="jcsm12228-li-0016"><p>Screening</p></list-item><list-item id="jcsm12228-li-0017"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Exercise tolerance and muscle function</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0013"><list-item id="jcsm12228-li-0018"><p>Grip strength</p></list-item><list-item id="jcsm12228-li-0019"><p>Six min walk test with the Borg scale<xref rid="jcsm12228-bib-0026" ref-type="ref">26</xref>
</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0014"><list-item id="jcsm12228-li-0020"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Inflammation</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0015"><list-item id="jcsm12228-li-0021"><p>Fasting plasma CRP, TNF, interleukin&#x02010;6, and interleukin&#x02010;8 levels</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0016"><list-item id="jcsm12228-li-0022"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Appetite</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0017"><list-item id="jcsm12228-li-0023"><p>Food diaries</p></list-item><list-item id="jcsm12228-li-0024"><p>Functional Assessment of Anorexia/Cachexia Therapy questionnaire<xref rid="jcsm12228-bib-0025" ref-type="ref">25</xref>
</p></list-item><list-item id="jcsm12228-li-0025"><p>Council on Nutrition Appetite Questionnaire<xref rid="jcsm12228-bib-0024" ref-type="ref">24</xref>
</p></list-item><list-item id="jcsm12228-li-0026"><p>A study&#x02010;specific palatability questionnaire (detailed in supplementary material 6)</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0018"><list-item id="jcsm12228-li-0027"><p>Screening, baseline, and week 12</p></list-item><list-item id="jcsm12228-li-0028"><p>Baseline, week 6, and week 12</p></list-item><list-item id="jcsm12228-li-0029"><p>Baseline, week 6, and week 12</p></list-item><list-item id="jcsm12228-li-0030"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Glucose metabolism</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0019"><list-item id="jcsm12228-li-0031"><p>Fasting blood glucose and serum insulin levels</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0020"><list-item id="jcsm12228-li-0032"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lipid metabolism</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0021"><list-item id="jcsm12228-li-0033"><p>Fasting plasma total cholesterol, triglyceride, and HDL and LDL cholesterol levels</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0022"><list-item id="jcsm12228-li-0034"><p>Baseline, week 6, and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Daily activity</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0023"><list-item id="jcsm12228-li-0035"><p>Daily walking distance measured by pedometer</p></list-item><list-item id="jcsm12228-li-0036"><p>Amount of self&#x02010;reported exercise</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0024"><list-item id="jcsm12228-li-0037"><p>Daily</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fat mass</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0025"><list-item id="jcsm12228-li-0038"><p>Dual&#x02010;energy X&#x02010;ray absorptiometry, analysed centrally by BioClinica<sup>&#x000ae;</sup>
</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0026"><list-item id="jcsm12228-li-0039"><p>Baseline and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lean body mass</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0027"><list-item id="jcsm12228-li-0040"><p>Dual&#x02010;energy X&#x02010;ray absorptiometry, analysed centrally by BioClinica<sup>&#x000ae;</sup>
</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0028"><list-item id="jcsm12228-li-0041"><p>Baseline and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lung function</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0029"><list-item id="jcsm12228-li-0042"><p>FEV<sub>1</sub>
</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0030"><list-item id="jcsm12228-li-0043"><p>Screening, baseline and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HRQoL</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0031"><list-item id="jcsm12228-li-0044"><p>COPD Assessment Test<xref rid="jcsm12228-bib-0023" ref-type="ref">23</xref>
</p></list-item><list-item id="jcsm12228-li-0045"><p>COPD Clinical Questionnaire<xref rid="jcsm12228-bib-0022" ref-type="ref">22</xref>
</p></list-item><list-item id="jcsm12228-li-0046"><p>St. George's Respiratory Questionnaire for COPD patients<xref rid="jcsm12228-bib-0021" ref-type="ref">21</xref>
</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0032"><list-item id="jcsm12228-li-0047"><p>Baseline and week 12</p></list-item></list>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Compliance</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0033"><list-item id="jcsm12228-li-0048"><p>Fasting plasma omega&#x02010;3 and omega&#x02010;6 levels (omega&#x02010;3 to omega&#x02010;6 ratio) and vitamin D3 levels</p></list-item><list-item id="jcsm12228-li-0049"><p>Study&#x02010;specific drink consumption diary</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0034"><list-item id="jcsm12228-li-0050"><p>Baseline and week 12</p></list-item><list-item id="jcsm12228-li-0051"><p>Throughout the study period</p></list-item></list>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Exploratory efficacy endpoints</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">COPD progression</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0035"><list-item id="jcsm12228-li-0052"><p>Proportion of patients experiencing a COPD exacerbation</p></list-item><list-item id="jcsm12228-li-0053"><p>Proportion of patients experiencing a COPD progression, defined as change or addition of medication, or worsening of disease</p></list-item></list>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<list list-type="bullet" id="jcsm12228-list-0036"><list-item id="jcsm12228-li-0054"><p>Throughout the study period</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="jcsm12228-note-0001"><p>ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disease; CRP, C&#x02010;reactive protein; FEV<sub>1</sub>, forced expiratory volume in 1&#x000a0;s; HDL, high&#x02010;density lipoprotein; HRQoL, health&#x02010;related quality of life; LDL, low&#x02010;density lipoprotein; TNF, tumour necrosis factor.</p></fn></table-wrap-foot></table-wrap><p>Secondary endpoints included change from baseline to weeks 6 and 12 in BMI, weight and waist and calf circumference, and inflammatory biomarkers. Changes in exercise tolerance and muscle function, appetite, and glucose and lipid metabolism were evaluated at the same time points. Changes in fat mass (FM), lean body mass (LBM), lung function, and HRQoL from baseline to week 12 were also assessed. Plasma EPA and DHA levels were also measured. Compliance was assessed based on drink consumption diaries and changes in omega&#x02010;3 to omega&#x02010;6 (O3:O6) ratio and vitamin D3 levels from baseline to week 12. Numbers of patients experiencing exacerbations and signs of COPD progression (defined as an AE related to COPD, addition of a new COPD&#x02010;related medication, or an increase in dose in existing COPD medication) were examined as exploratory efficacy endpoints.</p></sec><sec id="jcsm12228-sec-0011"><title>Statistical analysis</title><p>Safety and efficacy analyses were performed for the safety and full analysis sets, respectively. Safety endpoints were summarized using descriptive statistics: differences reported are numerical only, unless otherwise specified. For continuous efficacy endpoints, differences between treatment groups from baseline to weeks 6 or 12 were assessed using analyses of covariance (ANCOVA) with baseline value as the covariate.</p><p>Greater than expected reductions in the safety endpoint of blood pressure (BP) were observed between baseline and week 12, so a <italic>post hoc</italic> ANCOVA was conducted using treatment as the fixed factor and baseline value as the covariate for this endpoint; because of observed differences in inflammation between groups, EPA and DHA levels were also assessed in the same type of <italic>post hoc</italic> analysis.</p><p>Significant differences between groups in disease severity [assessed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria] and FEV<sub>1</sub> were observed at baseline. Therefore, <italic>post hoc</italic> ANCOVAs were conducted with stage of COPD [moderate vs. severe, assessed by GOLD criteria (<italic>Table</italic>&#x000a0;<xref rid="jcsm12228-tbl-0001" ref-type="table-wrap">1</xref>)] as a factor, for efficacy endpoints in which treatment effects of <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.1 were observed in one or more variables in an efficacy outcome category in the primary analysis; treatment and stage of COPD were fixed factors, and baseline value was a covariate.</p><p>All tests were two&#x02010;sided, and <italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.05 was considered significant. No adjustments were made for multiple comparisons owing to the exploratory nature of the analysis. Data were analysed using Statistical Analysis System (v9.3) software. Unless otherwise specified, data in parentheses show mean change from baseline to week 12 in the TMN group vs. the isocaloric comparator group, alongside baseline&#x02010;adjusted <italic>P</italic> values. Disease severity&#x02010;adjusted and baseline&#x02010;adjusted <italic>P</italic> values are provided where specified.</p></sec></sec><sec id="jcsm12228-sec-0012"><title>Results</title><p>Between 7 May 2015 and 5 April 2016, 48 patients were screened, and 45 were randomized to receive TMN (<italic>n</italic>&#x000a0;=&#x000a0;22) or comparator (<italic>n</italic>&#x000a0;=&#x000a0;23). <italic>Figure</italic>
<xref rid="jcsm12228-fig-0001" ref-type="fig">1</xref> shows patient flow. Baseline characteristics, including age, weight loss, and proportion of patients with cachexia, did not differ between groups (<italic>Table</italic>
<xref rid="jcsm12228-tbl-0002" ref-type="table-wrap">2</xref>). The proportion of women was slightly, but not significantly, higher in the TMN group than the comparator group (<italic>P&#x000a0;&#x0003e;</italic>&#x000a0;0.1). A greater proportion of patients in the TMN vs. the comparator group had severe disease based on GOLD criteria at baseline; this was accounted for in <italic>post hoc</italic> analyses.</p><fig fig-type="Figure" xml:lang="en" id="jcsm12228-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient flow.</p></caption><graphic id="nlm-graphic-1" xlink:href="JCSM-9-28-g001"/></fig><table-wrap id="jcsm12228-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline patient demographics and characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Mean</td><td align="left" valign="top" rowspan="1" colspan="1">SD</td><td align="left" valign="top" rowspan="1" colspan="1">Mean</td><td align="left" valign="top" rowspan="1" colspan="1">SD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">69.2</td><td align="left" valign="top" rowspan="1" colspan="1">6.3</td><td align="left" valign="top" rowspan="1" colspan="1">69.7</td><td align="left" valign="top" rowspan="1" colspan="1">8.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">64.1</td><td align="left" valign="top" rowspan="1" colspan="1">10.8</td><td align="left" valign="top" rowspan="1" colspan="1">69.4</td><td align="left" valign="top" rowspan="1" colspan="1">15.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight loss (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1</td><td align="left" valign="top" rowspan="1" colspan="1">2.5</td><td align="left" valign="top" rowspan="1" colspan="1">4.0</td><td align="left" valign="top" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (cm)</td><td align="left" valign="top" rowspan="1" colspan="1">168.9</td><td align="left" valign="top" rowspan="1" colspan="1">9.0</td><td align="left" valign="top" rowspan="1" colspan="1">171.3</td><td align="left" valign="top" rowspan="1" colspan="1">8.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">22.5</td><td align="left" valign="top" rowspan="1" colspan="1">3.7</td><td align="left" valign="top" rowspan="1" colspan="1">23.5</td><td align="left" valign="top" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub> (% of FVC)</td><td align="left" valign="top" rowspan="1" colspan="1">45.0<xref ref-type="fn" rid="jcsm12228-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">10.0</td><td align="left" valign="top" rowspan="1" colspan="1">52.4</td><td align="left" valign="top" rowspan="1" colspan="1">8.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">54.5</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">43.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Severe COPD based on GOLD criteria<xref ref-type="fn" rid="jcsm12228-note-0004">b</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">15<xref ref-type="fn" rid="jcsm12228-note-0003">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">68.2</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">34.8</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Weight loss</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No weight history</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">9.1</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">8.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No weight loss<xref ref-type="fn" rid="jcsm12228-note-0005">c</xref> and BMI 16&#x02013;18&#x000a0;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">4.5</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">4.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&#x02264;5% weight loss<xref ref-type="fn" rid="jcsm12228-note-0005">c</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">50.0</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">52.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5&#x02013;10% weight loss<xref ref-type="fn" rid="jcsm12228-note-0005">c</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">36.4</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">34.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stage of cachexia according to the ERS statement<xref rid="jcsm12228-bib-0016" ref-type="ref">16</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pre&#x02010;cachexia<xref ref-type="fn" rid="jcsm12228-note-0006">d</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">4.5</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">8.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cachexia<xref ref-type="fn" rid="jcsm12228-note-0007">e</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">31.8</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">26.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking status</td><td colspan="2" align="left" valign="top" rowspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;21</td><td colspan="2" align="left" valign="top" rowspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;22</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Current</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">61.9</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">50.0</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Former</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">38.1</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">50.0</td></tr></tbody></table><table-wrap-foot><fn id="jcsm12228-note-0002"><p>BMI, body mass index; COPD, chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV<sub>1</sub>, forced expiratory volume in 1&#x000a0;s; FFMI, fat&#x02010;free mass index; FVC, forced expiratory vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation; TMN, targeted medical nutrition.</p></fn><fn id="jcsm12228-note-0003"><label>a</label><p>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for the TMN vs. isocaloric comparator group.</p></fn><fn id="jcsm12228-note-0004"><label>b</label><p>FEV<sub>1</sub> 30&#x02013;50% of predicted value.</p></fn><fn id="jcsm12228-note-0005"><label>c</label><p>Over the 12&#x000a0;months before randomization.</p></fn><fn id="jcsm12228-note-0006"><label>d</label><p>Unintentional weight loss of &#x0003e;5%.</p></fn><fn id="jcsm12228-note-0007"><label>e</label><p>Unintentional weight loss of &#x0003e;5% and FFMI &#x0003c;17&#x000a0;kg/m<sup>2</sup> (for men) or &#x0003c;15&#x000a0;kg/m<sup>2</sup> (for women).</p></fn></table-wrap-foot></table-wrap><sec id="jcsm12228-sec-0013"><title>Safety</title><p>Targeted medical nutrition was well tolerated, and AEs did not differ in number or type between the TMN and comparator groups (36 AEs in 16 patients vs. 36 AEs in 17 patients, respectively), with the exception of diarrhoea, which occurred in a greater number of patients in the comparator group (1 vs. 5 patients, respectively). Approximately one&#x02010;third of AEs were considered treatment&#x02010;related (<italic>Table</italic>
<xref rid="jcsm12228-tbl-0003" ref-type="table-wrap">3</xref> (a)). Four serious AEs occurred (TMN: death and inguinal hernia; comparator: arteriosclerosis event and pulmonary embolism), but none was considered related to treatment by the investigator.</p><table-wrap id="jcsm12228-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Safety parameters in the targeted medical nutrition and isocaloric comparator groups: (a) treatment&#x02010;related adverse events deemed to be related to study products by the investigator, (b) vital signs, (c) proportion of patients with abnormal outcomes in physical examinations, and (d) laboratory safety parameters</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">(a)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adverse events</th><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1"/><th colspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1"/></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Severity</td><td colspan="2" align="left" valign="top" rowspan="1">Mild <italic>n</italic> (%)</td><td colspan="2" align="left" valign="top" rowspan="1">Moderate <italic>n</italic> (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Event<xref ref-type="fn" rid="jcsm12228-note-0009">a</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</td><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="5" align="left" valign="top" rowspan="1">Gastrointestinal disorders</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Constipation</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diarrhoea</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2 (8.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Flatulence</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Gastro&#x02010;oesophageal reflux disease</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="left" valign="top" rowspan="1" colspan="1">2 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="5" align="left" valign="top" rowspan="1">Metabolism and nutrition disorders</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="5" align="left" valign="top" rowspan="1">Nervous system disorders</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="5" align="left" valign="top" rowspan="1">Respiratory, thoracic, and mediastinal disorders</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Increased viscosity of bronchial secretion</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(b)</td><td align="left" valign="top" rowspan="1" colspan="1">Vital signs</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="left" valign="top" rowspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">
Baseline<break/>
Mean (SD)</td><td colspan="2" align="left" valign="top" rowspan="1">
Week 12<break/>
Mean (SD)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</td><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Systolic BP (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">144.7 (22.7)</td><td align="left" valign="top" rowspan="1" colspan="1">141.6 (17.8)</td><td align="left" valign="top" rowspan="1" colspan="1">129.4 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">142.7 (19.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Diastolic BP (mmHg)</td><td align="left" valign="top" rowspan="1" colspan="1">81.6 (10.1)</td><td align="left" valign="top" rowspan="1" colspan="1">78.0 (10.2)</td><td align="left" valign="top" rowspan="1" colspan="1">75.8 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">78.6 (10.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="left" valign="top" rowspan="1" colspan="1">75.1 (11.9)</td><td align="left" valign="top" rowspan="1" colspan="1">75.74 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">76.9 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">77.1 (10.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(c)</td><td align="left" valign="top" rowspan="1" colspan="1">Physical examination</td><td colspan="2" align="left" valign="top" rowspan="1"/><td colspan="2" align="left" valign="top" rowspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">Baseline <italic>n</italic> (%)</td><td colspan="2" align="left" valign="top" rowspan="1">Week 12 <italic>n</italic> (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Abnormal observations</td><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;23)</td><td align="left" valign="top" rowspan="1" colspan="1">TMN (<italic>n</italic>&#x000a0;=&#x000a0;20)</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator (<italic>n</italic>&#x000a0;=&#x000a0;19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Abdomen</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Cardiovascular system</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Skin</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Nervous system</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Respiratory system</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">(d)</td><td colspan="3" align="left" valign="top" rowspan="1">Laboratory parameters</td><td colspan="2" align="left" valign="top" rowspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">
Baseline<break/>
Mean (SD)</td><td colspan="2" align="left" valign="top" rowspan="1">
Week 12<break/>
Mean (SD)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">TMN</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator</td><td align="left" valign="top" rowspan="1" colspan="1">TMN</td><td align="left" valign="top" rowspan="1" colspan="1">Comparator</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Clinical chemistry parameters</td><td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;22)</td><td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;23)</td><td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;19)</td><td align="left" valign="top" rowspan="1" colspan="1">(<italic>n</italic>&#x000a0;=&#x000a0;19)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ALP (&#x003bc;kat/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.16 (0.35)</td><td align="left" valign="top" rowspan="1" colspan="1">1.22 (0.27)</td><td align="left" valign="top" rowspan="1" colspan="1">1.17 (0.34)</td><td align="left" valign="top" rowspan="1" colspan="1">1.25 (0.31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ALT (&#x003bc;kat/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.37 (0.20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.37 (0.12)</td><td align="left" valign="top" rowspan="1" colspan="1">0.43 (0.20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.37 (0.12)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AST (&#x003bc;kat/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.40 (0.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.39 (0.12)</td><td align="left" valign="top" rowspan="1" colspan="1">0.43 (0.16)</td><td align="left" valign="top" rowspan="1" colspan="1">0.38 (0.09)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Bilirubin (&#x003bc;mol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">6.55 (2.34)</td><td align="left" valign="top" rowspan="1" colspan="1">7.00 (3.71)</td><td align="left" valign="top" rowspan="1" colspan="1">5.63 (2.09)</td><td align="left" valign="top" rowspan="1" colspan="1">6.74 (4.53)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Creatinine (&#x003bc;mol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">74.82 (20.12)</td><td align="left" valign="top" rowspan="1" colspan="1">78.13 (21.48)</td><td align="left" valign="top" rowspan="1" colspan="1">71.74 (24.40)</td><td align="left" valign="top" rowspan="1" colspan="1">78.58 (18.57)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Potassium (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">4.32 (0.41)</td><td align="left" valign="top" rowspan="1" colspan="1">4.10 (0.34)</td><td align="left" valign="top" rowspan="1" colspan="1">4.14 (0.31)</td><td align="left" valign="top" rowspan="1" colspan="1">4.13 (0.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">140.23 (2.47)</td><td align="left" valign="top" rowspan="1" colspan="1">139.52 (2.61)</td><td align="left" valign="top" rowspan="1" colspan="1">138.74 (2.68)</td><td align="left" valign="top" rowspan="1" colspan="1">139.68 (1.73)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Haematological parameters</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;21</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;22</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;20</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic>n</italic>&#x000a0;=&#x000a0;19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Haematocrit</td><td align="left" valign="top" rowspan="1" colspan="1">0.46 (0.04)</td><td align="left" valign="top" rowspan="1" colspan="1">0.44 (0.03)</td><td align="left" valign="top" rowspan="1" colspan="1">0.47 (0.04)</td><td align="left" valign="top" rowspan="1" colspan="1">0.44 (0.04)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Haemoglobin (g/L)</td><td align="left" valign="top" rowspan="1" colspan="1">146.10 (11.30)</td><td align="left" valign="top" rowspan="1" colspan="1">140.32 (12.32)</td><td align="left" valign="top" rowspan="1" colspan="1">146.70 (10.07)</td><td align="left" valign="top" rowspan="1" colspan="1">139.74 (12.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Platelet count (&#x000d7;10<sup>9</sup>/L)</td><td align="left" valign="top" rowspan="1" colspan="1">303.24 (97.21)</td><td align="left" valign="top" rowspan="1" colspan="1">295.23 (85.97)</td><td align="left" valign="top" rowspan="1" colspan="1">283.30 (89.91)</td><td align="left" valign="top" rowspan="1" colspan="1">295.63 (78.31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Red blood cell count (&#x000d7;10<sup>12</sup>/L)</td><td align="left" valign="top" rowspan="1" colspan="1">4.82 (0.56)</td><td align="left" valign="top" rowspan="1" colspan="1">4.65 (0.44)</td><td align="left" valign="top" rowspan="1" colspan="1">4.86 (0.47)</td><td align="left" valign="top" rowspan="1" colspan="1">4.62 (0.47)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">White blood cell differential count (&#x000d7;10<sup>9</sup>/L)</td><td align="left" valign="top" rowspan="1" colspan="1">7.71 (2.15)</td><td align="left" valign="top" rowspan="1" colspan="1">7.14 (2.33)</td><td align="left" valign="top" rowspan="1" colspan="1">8.08 (2.35)</td><td align="left" valign="top" rowspan="1" colspan="1">7.15 (2.45)</td></tr></tbody></table><table-wrap-foot><fn id="jcsm12228-note-0008"><p>ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; bpm, beats per minute; SD, standard deviation; TMN, targeted medical nutrition.</p></fn><fn id="jcsm12228-note-0009"><label>a</label><p>Common chronic obstructive pulmonary disease complications including breathlessness, wheezing, coughing, and sputum production were not reported as adverse events unless they were considered to be serious.</p></fn></table-wrap-foot></table-wrap><p>Changes in mean BP from baseline to week 12 were greater than expected in the TMN group, but no patient experienced hypotension; heart rate was numerically similar between groups at both time points (<italic>Table</italic>
<xref rid="jcsm12228-tbl-0003" ref-type="table-wrap">3</xref>). Mean systolic BP decreased in the TMN but not the comparator group (&#x02212;12.7 vs. +0.2&#x000a0;mmHg; <italic>P</italic>&#x000a0;=&#x000a0;0.0118); this difference remained significant after correction for disease severity (<italic>P&#x000a0;=</italic>&#x000a0;0.0418). Mean diastolic BP decreased from &#x0003e;90 to &#x02264;90&#x000a0;mmHg in 20.0 and 5.3% of patients in the TMN and comparator groups, respectively (Table&#x000a0;<xref rid="jcsm12228-supitem-0002" ref-type="supplementary-material">S2</xref>); the between&#x02010;group difference in mean diastolic BP was not significant (&#x02212;3.9 vs. +0.8&#x000a0;mmHg; <italic>P</italic>&#x000a0;=&#x000a0;0.2445). Physical examination outcomes, laboratory safety assessment results (<italic>Table</italic>
<xref rid="jcsm12228-tbl-0003" ref-type="table-wrap">3</xref>), and concomitant medication use initiated post&#x02010;baseline (Table&#x000a0;<xref rid="jcsm12228-supitem-0003" ref-type="supplementary-material">S3</xref>) did not differ numerically between groups.</p></sec><sec id="jcsm12228-sec-0014"><title>Body composition and weight</title><p>Patients in TMN and comparator groups gained similar amounts of weight, and thus, BMI rose similarly (Table&#x000a0;<xref rid="jcsm12228-supitem-0004" ref-type="supplementary-material">S4</xref>). There were no between&#x02010;group differences in changes in waist and calf circumference, appendicular LBM, or skeletal muscle index; however, the TMN group gained significantly more FM than the comparator group (+1.87 vs. +0.60&#x000a0;kg; <italic>P</italic>&#x000a0;=&#x000a0;0.0013), and a difference was evident regardless of baseline weight loss (Table&#x000a0;<xref rid="jcsm12228-supitem-0005" ref-type="supplementary-material">S5</xref>). This difference remained after adjustment for COPD severity (<italic>P&#x000a0;=</italic>&#x000a0;0.0013).</p></sec><sec id="jcsm12228-sec-0015"><title>Exercise tolerance and muscle function</title><p>Borg scale&#x02010;assessed fatigue after the 6&#x000a0;min walk test was significantly reduced in the TMN vs. comparator group by week 12; a similar pattern was observed for dyspnoea, although the difference missed statistical significance (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0002" ref-type="fig">2</xref>A). When accounting for COPD severity, reductions in fatigue (<italic>P&#x000a0;=</italic>&#x000a0;0.0223) and dyspnoea (<italic>P&#x000a0;=</italic>&#x000a0;0.0382) in the TMN group were both significant. Changes in exercise tolerance were similar regardless of weight loss at baseline (Table&#x000a0;<xref rid="jcsm12228-supitem-0005" ref-type="supplementary-material">S5</xref>). Change in 6&#x000a0;min walk distance from baseline to week 12 did not differ significantly between groups (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0002" ref-type="fig">2</xref>B), and neither did hand grip strength or amount of self&#x02010;reported exercise.</p><fig fig-type="Figure" xml:lang="en" id="jcsm12228-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Change from baseline to week 12 in results of the 6&#x000a0;min walk test in the TMN group and the isocaloric comparator group. (A) Borg scale measured post&#x02010;walk fatigue and dyspnoea. (B) Distance covered. Data on figures show mean&#x000a0;&#x000b1;&#x000a0;SEM change from baseline to week 12, calculated as week 12 value minus baseline value for each patient, divided by the <italic>n</italic> number; <italic>n</italic>&#x000a0;=&#x000a0;19 for both groups. Data below figures show mean baseline and week 12 values, calculated as the mean of all values recorded. Effect sizes and <italic>P</italic> values were estimated by analysis of covariance adjusted for baseline value. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 for the TMN vs. isocaloric comparator group. CI, confidence interval; SEM, standard error of the mean; TMN, targeted medical nutrition.</p></caption><graphic id="nlm-graphic-3" xlink:href="JCSM-9-28-g002"/></fig></sec><sec id="jcsm12228-sec-0016"><title>Inflammation</title><p>Fasting plasma concentrations of all four biomarkers of inflammation were numerically lower in the TMN vs. comparator group at weeks 6 and 12. Concentrations of IL&#x02010;6, IL&#x02010;8, and tumour necrosis factor decreased in the TMN group and increased in the comparator group over 12&#x000a0;weeks, whereas C&#x02010;reactive protein concentrations increased in both groups (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0003" ref-type="fig">3</xref>). These differences were not significant, before or after taking disease severity into account, but were similar in patients with &#x0003e;5 and &#x02264;5% weight loss at baseline (Table&#x000a0;<xref rid="jcsm12228-supitem-0005" ref-type="supplementary-material">S5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jcsm12228-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Change in levels of markers of inflammation from baseline to week 12 in the TMN group and the isocaloric comparator group. Data on figures show mean&#x000a0;&#x000b1;&#x000a0;SEM change from baseline to week 12, calculated as week 12 value minus baseline value for each patient, divided by the <italic>n</italic> number; <italic>n</italic>&#x000a0;=&#x000a0;22 for both groups. Data below figures show mean baseline and week 12 values, calculated as the mean of all values recorded. Effect sizes and <italic>P</italic> values were estimated by analysis of covariance adjusted for baseline value. CI, confidence interval; CRP, C&#x02010;reactive protein; IL, interleukin; SEM, standard error of the mean; TMN, targeted medical nutrition; TNF, tumour necrosis factor.</p></caption><graphic id="nlm-graphic-5" xlink:href="JCSM-9-28-g003"/></fig></sec><sec id="jcsm12228-sec-0017"><title>Metabolic biomarkers</title><p>Fasting plasma low&#x02010;density lipoprotein [(LDL): +0.29 vs. &#x02212;0.21&#x000a0;mmol/L] and high&#x02010;density lipoprotein [(HDL) +0.13 vs. &#x02212;0.04&#x000a0;mmol/L] cholesterol levels increased over the study period in the TMN but not the comparator group, while the opposite was true for triglyceride levels (&#x02212;0.21 vs. +0.06&#x000a0;mmol/L). Differences in LDL and triglycerides were significant before (LDL: <italic>P</italic>&#x000a0;=&#x000a0;0.0226; triglycerides: <italic>P</italic>&#x000a0;=&#x000a0;0.0286) and after correcting for COPD severity (LDL: <italic>P</italic>&#x000a0;=&#x000a0;0.0325; triglycerides: <italic>P</italic>&#x000a0;=&#x000a0;0.0217), whereas differences in HDL levels were significant only after correction (<italic>P</italic>&#x000a0;=&#x000a0;0.0254). These changes were evident regardless of weight loss at baseline. Total cholesterol, HDL:LDL ratio, and fasting blood glucose and serum insulin level changes did not differ between groups.</p></sec><sec id="jcsm12228-sec-0018"><title>Health&#x02010;related quality of life</title><p>Overall scores on the St. George's Respiratory Questionnaire (SGRQ) did not differ between groups, but scores on the activity subdomain significantly improved in the TMN vs. comparator group (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0004" ref-type="fig">4</xref>). This difference was not significant when accounting for disease severity (<italic>P</italic>&#x000a0;=&#x000a0;0.0592). There were no between&#x02010;group differences in changes in COPD Assessment Test and COPD Clinical Questionnaire scores.</p><fig fig-type="Figure" xml:lang="en" id="jcsm12228-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Change from baseline to week 12 in scores on the St. George's Respiratory Questionnaire in the TMN group and the isocaloric comparator group. Data on figures show mean&#x000a0;&#x000b1;&#x000a0;SEM change from baseline to week 12, calculated as week 12 value minus baseline value for each patient, divided by the <italic>n</italic> number; <italic>n</italic>&#x000a0;=&#x000a0;22 for both groups. Data below figures show mean baseline and week 12 values, calculated as the mean of all values recorded. Effect sizes and <italic>P</italic> values were estimated by analysis of covariance adjusted for baseline value. CI, confidence interval; SEM, standard error of the mean; TMN, targeted medical nutrition.</p></caption><graphic id="nlm-graphic-7" xlink:href="JCSM-9-28-g004"/></fig></sec><sec id="jcsm12228-sec-0019"><title>Compliance</title><p>Compliance was good in the TMN (79%) and comparator (77%) groups based on drink consumption diaries. Furthermore, O3:O6 ratio and vitamin D3 levels increased significantly in the TMN vs. comparator group (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0005" ref-type="fig">5</xref>), and between&#x02010;group differences remained when accounting for disease severity (O3:O6 ratio: <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; vitamin D3: <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). At baseline, EPA and DHA comprised a small proportion of the total plasma fatty acids in both groups [mean&#x000a0;&#x000b1;&#x000a0;standard error of the mean (SEM), EPA: 1.30&#x000a0;&#x000b1;&#x000a0;0.17 vs. 1.14&#x000a0;&#x000b1;&#x000a0;0.09%; DHA: 2.43&#x000a0;&#x000b1;&#x000a0;0.14 vs. 2.25&#x000a0;&#x000b1;&#x000a0;0.14%], while by week 12, the proportion of these PUFAs had increased significantly in the TMN vs. the comparator group (<italic>Figure</italic>
<xref rid="jcsm12228-fig-0005" ref-type="fig">5</xref>). These changes were apparent after correcting for disease severity (EPA: <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; DHA: <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001).</p><fig fig-type="Figure" xml:lang="en" id="jcsm12228-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Change from baseline to week 12 in the TMN group and the isocaloric comparator group. (A) Plasma omega&#x02010;3 to omega&#x02010;6 ratio. (B) Plasma vitamin D3 level. (C) EPA as a proportion of total plasma fatty acids. (D) DHA as a proportion of total plasma fatty acids. Data on figures show mean&#x000a0;&#x000b1;&#x000a0;SEM change from baseline to week 12, calculated as week 12 value minus baseline value for each patient, divided by the <italic>n</italic> number; TMN group, <italic>n</italic>&#x000a0;=&#x000a0;22; comparator group; <italic>n</italic>&#x000a0;=&#x000a0;22&#x02013;23. Data below figures show mean baseline and week 12 values, calculated as the mean of all values recorded. Effect sizes and <italic>P</italic> values were estimated by analysis of covariance adjusted for baseline value. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001 for the TMN group vs. the isocaloric comparator group. CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; SEM, standard error of the mean; TMN, targeted medical nutrition.</p></caption><graphic id="nlm-graphic-9" xlink:href="JCSM-9-28-g005"/></fig></sec><sec id="jcsm12228-sec-0020"><title>Appetite and calorie intake</title><p>Changes in scores on the Functional Assessment of Anorexia/Cachexia Therapy questionnaire, Council on Nutrition Appetite Questionnaire, and palatability questionnaire were minor and did not differ between groups. Changes in self&#x02010;reported calorie intake were minor and did not differ significantly between the groups by week 12 (<italic>P</italic>&#x000a0;=&#x000a0;0.8381).</p></sec><sec id="jcsm12228-sec-0021"><title>Chronic obstructive pulmonary disease progression</title><p>In total, 40.9% (<italic>n</italic>&#x000a0;=&#x000a0;9) of patients in the TMN group vs. 50% (<italic>n</italic>&#x000a0;=&#x000a0;11) of those in the comparator group experienced COPD progression, as defined by the criteria used in this study. COPD exacerbations were experienced by numerically fewer individuals in the TMN than the comparator group [4.5% (<italic>n</italic>&#x000a0;=&#x000a0;1) vs. 13.6% (<italic>n</italic>&#x000a0;=&#x000a0;3), respectively]. There was no between&#x02010;group difference in the change in mean FEV<sub>1</sub> over time (<italic>P</italic>&#x000a0;=&#x000a0;0.3689).</p></sec></sec><sec id="jcsm12228-sec-0022"><title>Discussion</title><p>Targeted nutritional supplementation was well tolerated and had clinical benefits in pre&#x02010;cachectic and cachectic patients with COPD, in this first of its kind study evaluating the safety and efficacy of a complex, targeted nutritional supplement relative to an isocaloric comparator.</p><p>No safety issues were observed, while compliance with both products was high. AE profiles were similar in both groups; diarrhoea was more common in the comparator group, possibly because the comparator was milk&#x02010;based, as are most currently available nutritional supplements. Safety parameters were comparable between the two groups, with the exception that patients receiving TMN benefited from reduced systolic BP. Patients with a high baseline BP seemed to benefit the most, as expected based on previous studies of high&#x02010;dose omega&#x02010;3 PUFAs,<xref rid="jcsm12228-bib-0027" ref-type="ref">27</xref> which is noteworthy given that hypertension is commonly comorbid with COPD.<xref rid="jcsm12228-bib-0028" ref-type="ref">28</xref>
</p><p>Targeted medical nutrition was associated with a consistent trend towards reduced inflammation relative to the isocaloric comparator. This effect was apparent even though elevated baseline inflammatory biomarker levels were not a requirement for inclusion in this trial. Whether the anti&#x02010;inflammatory effects were due to increases in plasma DHA or EPA levels is debatable,<xref rid="jcsm12228-bib-0029" ref-type="ref">29</xref> but both omega&#x02010;3 PUFAs are known anti&#x02010;inflammatory agents, thought to act by several mechanisms including altering cell membrane phospholipid fatty acid composition and inhibiting pro&#x02010;inflammatory and activating anti&#x02010;inflammatory transcription factors.<xref rid="jcsm12228-bib-0030" ref-type="ref">30</xref>
</p><p>Targeted medical nutrition had positive effects on measures of exercise tolerance. Exercise&#x02010;induced dyspnoea and fatigue were better by a clinically relevant degree (&#x0003e;1 point)<xref rid="jcsm12228-bib-0031" ref-type="ref">31</xref> in patients receiving TMN vs. isocaloric comparator by week 12, and the mean difference between the groups in the change in 6&#x000a0;min walk distance was near the level of improvement that has been reported as clinically important (&#x02265;25&#x000a0;m).<xref rid="jcsm12228-bib-0032" ref-type="ref">32</xref> However, this study may not have been adequately powered to detect a difference in the latter statistically. Although it might be expected that exercise&#x02010;induced fatigue and exercise capacity improve concurrently, the two may not be directly linked, because fatigue has several precipitating factors.<xref rid="jcsm12228-bib-0033" ref-type="ref">33</xref> Greater improvements in 6&#x000a0;min walk test results might have been expected had the trial been longer, or had an exercise programme been included, as demonstrated previously in malnourished patients with COPD.<xref rid="jcsm12228-bib-0010" ref-type="ref">10</xref> A clinically relevant improvement in activity&#x02010;related quality of life, as measured by the SGRQ, was also notable in the TMN group.<xref rid="jcsm12228-bib-0034" ref-type="ref">34</xref> Although nutrition is only one of many variables affecting HRQoL, improved exercise tolerance has previously been linked with better HRQoL in COPD.<xref rid="jcsm12228-bib-0004" ref-type="ref">4</xref>, <xref rid="jcsm12228-bib-0035" ref-type="ref">35</xref>
</p><p>A major goal for improving the prognosis of patients with COPD is reversal of unintentional weight loss.<xref rid="jcsm12228-bib-0036" ref-type="ref">36</xref> Weight increased in both groups in this trial and an increase in FM was associated with TMN. Furthermore, this benefit was evident both in patients with pre&#x02010;cachexia (&#x02264;5% weight loss) and those with cachexia (&#x0003e;5% weight loss), despite the broad definitions of these syndromes used in this study. As the calorie intake derived from study products was similar in both groups, this change in body composition is likely a result of the unique combination of ingredients in the TMN. Although an increase in LBM would have been preferable, this might have been achieved had an exercise programme been specified, as was recently demonstrated in an RCT of a nutritional intervention combined with high&#x02010;intensity exercise in patients with COPD and low muscle mass.<xref rid="jcsm12228-bib-0037" ref-type="ref">37</xref> Moreover, any weight gain in this patient group could be beneficial in terms of survival.<xref rid="jcsm12228-bib-0036" ref-type="ref">36</xref>
</p><p>The impact of TMN on lipid profiles was generally favourable, as expected based on studies of high&#x02010;dose omega&#x02010;3 PUFAs in healthy adults.<xref rid="jcsm12228-bib-0038" ref-type="ref">38</xref> Increases in fasting plasma HDL and decreases in triglycerides were promising, and as the HDL:LDL ratio did not change, no safety risk was indicated. Increases in LDL were presumably due to increases in particle size, from smaller, more atherogenic particles, to larger, less damaging particles.<xref rid="jcsm12228-bib-0039" ref-type="ref">39</xref> Insulin and glucose levels remained unchanged, most likely because patients were normoglycaemic at baseline.</p><p>This trial has several strengths compared with those reported previously. Firstly, interventions were well matched for energy content, allowing evaluation of the combination of ingredients in the TMN. Secondly, the patient withdrawal rate was low, and treatment compliance was high, despite the fish oil content of the TMN, as verified by significant enrichment of blood vitamin D3, EPA, and DHA levels. Finally, patients were well characterized. The main limitation of the study was its small sample size.</p></sec><sec id="jcsm12228-sec-0023"><title>Conclusions</title><p>This randomized, double&#x02010;blind, controlled trial demonstrated that this TMN containing high&#x02010;dose omega&#x02010;3 PUFAs, vitamin D, and high&#x02010;quality protein is well tolerated, with a good safety profile. Furthermore, TMN has positive effects on BP and blood lipids, and on exercise&#x02010;induced fatigue and dyspnoea, and therefore could be clinically beneficial in the nutritional and metabolic support of cachectic and pre&#x02010;cachectic patients with COPD.</p></sec><sec id="jcsm12228-sec-0027"><title>Conflict of interest</title><p>P.C.C. has received a research grant and personal fees from Smartfish. A.L. and M.M. have received personal fees from Smartfish. F.L. is a medical advisor to and has received personal fees from Smartfish. M.&#x000d6;. is an employee of Smartfish. A.S. has received fees from Smartfish and Nutricia to her institution.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jcsm12228-supitem-0001"><caption><p>
<bold>Table S1</bold> Inclusion and exclusion criteria</p></caption><media xlink:href="JCSM-9-28-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcsm12228-supitem-0002"><caption><p>
<bold>Table S2</bold> Numbers of patients with changes in BP from baseline to week 12 in the TMN and isocaloric comparator groups</p></caption><media xlink:href="JCSM-9-28-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcsm12228-supitem-0003"><caption><p>
<bold>Table S3</bold> Concomitant medications initiated post&#x02010;baseline in patients in the TMN and isocaloric comparator groups</p></caption><media xlink:href="JCSM-9-28-s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcsm12228-supitem-0004"><caption><p>
<bold>Table S4</bold> Weight and body composition of patients in the TMN and isocaloric comparator groups</p></caption><media xlink:href="JCSM-9-28-s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcsm12228-supitem-0005"><caption><p>
<bold>Table S5</bold> Changes in body composition, exercise tolerance, inflammation and metabolic markers from baseline to week 12 in patients in the TMN and isocaloric comparator group, by weight loss group</p></caption><media xlink:href="JCSM-9-28-s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcsm12228-supitem-0006"><caption><p>
<bold>Supplementary Material 6</bold>
</p></caption><media xlink:href="JCSM-9-28-s006.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jcsm12228-sec-0024"><title>Acknowledgements</title><p>The study was conducted in accordance with good clinical practice and the Declaration of Helsinki. All patients provided written informed consent. The study protocol and amendment were reviewed and approved by the Regional Ethics Committee in Gothenburg, Sweden.</p><p>All authors certify that they comply with the ethical guidelines for authorship and publishing in the <italic>Journal of Cachexia, Sarcopenia, and Muscle</italic>.<xref rid="jcsm12228-bib-0040" ref-type="ref">40</xref>
</p><p>The authors thank Harriet Crofts, PhD, and Katie Pillidge, PhD, of PharmaGenesis London, UK for medical writing support and editorial assistance in the preparation of this manuscript and Tommy Schyman for assistance with statistical analyses of the data, funded by Smartfish AB, Stockholm, Sweden.</p><p>This study was funded by Smartfish AB, Stockholm, Sweden.</p></ack><ref-list id="jcsm12228-bibl-0001" content-type="cited-references"><title>References</title><ref id="jcsm12228-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0002">
<string-name>
<surname>Muscaritoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Molfino</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lucia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rossi Fanelli</surname>
<given-names>F</given-names>
</string-name>. <article-title>Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach</article-title>. <source>Crit Rev Oncol Hematol</source>
<year>2015</year>;<volume>94</volume>:<fpage>251</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">25468676</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0003">
<string-name>
<surname>Onwuamaegbu</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Henein</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Cachexia in malaria and heart failure: therapeutic considerations in clinical practice</article-title>. <source>Postgrad Med J</source>
<year>2004</year>;<volume>80</volume>:<fpage>642</fpage>&#x02013;<lpage>649</lpage>.<pub-id pub-id-type="pmid">15537847</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0004">
<string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Broekhuizen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Weling&#x02010;Scheepers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>. <article-title>Body composition and mortality in chronic obstructive pulmonary disease</article-title>. <source>Am J Clin Nutr</source>
<year>2005</year>;<volume>82</volume>:<fpage>53</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">16002800</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0005">
<string-name>
<surname>Mostert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Goris</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Weling&#x02010;Scheepers</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease</article-title>. <source>Respir Med</source>
<year>2000</year>;<volume>94</volume>:<fpage>859</fpage>&#x02013;<lpage>867</lpage>.<pub-id pub-id-type="pmid">11001077</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0006">
<string-name>
<surname>Bernard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>LeBlanc</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Whittom</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Carrier</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jobin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Belleau</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Peripheral muscle weakness in patients with chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source>
<year>1998</year>;<volume>158</volume>:<fpage>629</fpage>&#x02013;<lpage>634</lpage>.<pub-id pub-id-type="pmid">9700144</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0007">
<string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Soeters</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Mostert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pluymers</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>. <article-title>Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo&#x02010;controlled randomized trial</article-title>. <source>Am J Respir Crit Care Med</source>
<year>1995</year>;<volume>152</volume>:<fpage>1268</fpage>&#x02013;<lpage>1274</lpage>.<pub-id pub-id-type="pmid">7551381</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0008">
<string-name>
<surname>Ferreira</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Brooks</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>R</given-names>
</string-name>. <article-title>Nutritional supplementation for stable chronic obstructive pulmonary disease</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2012</year>;<volume>12</volume>: CD000998.</mixed-citation></ref><ref id="jcsm12228-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0009">
<string-name>
<surname>Collins</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>Elia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stratton</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta&#x02010;analysis</article-title>. <source>Respirology</source>
<year>2013</year>;<volume>18</volume>:<fpage>616</fpage>&#x02013;<lpage>629</lpage>.<pub-id pub-id-type="pmid">23432923</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0010">
<string-name>
<surname>Broekhuizen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Creutzberg</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Weling&#x02010;Scheepers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>
<year>2005</year>;<volume>60</volume>:<fpage>376</fpage>&#x02013;<lpage>382</lpage>.<pub-id pub-id-type="pmid">15860712</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0011">
<string-name>
<surname>Sugawara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kasai</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kiyokawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujii</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Effects of nutritional supplementation combined with low&#x02010;intensity exercise in malnourished patients with COPD</article-title>. <source>Respir Med</source>
<year>2010</year>;<volume>104</volume>:<fpage>1883</fpage>&#x02013;<lpage>1889</lpage>.<pub-id pub-id-type="pmid">20627502</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0012">
<string-name>
<surname>Creutzberg</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Weling&#x02010;Scheepers</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Buurman</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>. <article-title>Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2000</year>;<volume>161</volume>:<fpage>745</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">10712317</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0013">
<string-name>
<surname>Malinovschi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Masoero</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bellocchia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ciuffreda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Solidoro</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mattei</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Severe vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients</article-title>. <source>Respir Res</source>
<year>2014</year>;<volume>15</volume>:<fpage>131</fpage>.<pub-id pub-id-type="pmid">25496239</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0014">
<string-name>
<surname>Biswas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Kirkham</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>
<given-names>I</given-names>
</string-name>. <article-title>Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease</article-title>. <source>Curr Med Chem</source>
<year>2013</year>;<volume>20</volume>:<fpage>1496</fpage>&#x02013;<lpage>1530</lpage>.<pub-id pub-id-type="pmid">22963552</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0015">
<string-name>
<surname>Devries</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Supplemental protein in support of muscle mass and health: advantage whey</article-title>. <source>J Food Sci</source>
<year>2015</year>;<volume>80</volume>:<fpage>A8</fpage>&#x02013;<lpage>A15</lpage>.<pub-id pub-id-type="pmid">25757896</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0016">
<string-name>
<surname>Muscaritoli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Argiles</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Aversa</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Biolo</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Consensus definition of sarcopenia, cachexia and pre&#x02010;cachexia: joint document elaborated by Special Interest Groups (SIG) &#x0201c;cachexia&#x02010;anorexia in chronic wasting diseases&#x0201d; and &#x0201c;nutrition in geriatrics&#x0201d;</article-title>. <source>Clin Nutr</source>
<year>2010</year>;<volume>29</volume>:<fpage>154</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">20060626</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0017">
<string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Ferreira</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Franssen</surname>
<given-names>FM</given-names>
</string-name>, <string-name>
<surname>Gosker</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Janssens</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Muscaritoli</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Nutritional assessment and therapy in COPD: a European Respiratory Society statement</article-title>. <source>Eur Respir J</source>
<year>2014</year>;<volume>44</volume>:<fpage>1504</fpage>&#x02013;<lpage>1520</lpage>.<pub-id pub-id-type="pmid">25234804</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0018">
<string-name>
<surname>Colomer</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Moreno&#x02010;Nogueira</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Luna</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;Peris</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Garcia&#x02010;de&#x02010;Lorenzo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zarazaga</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>N&#x02010;3 fatty acids, cancer and cachexia: a systematic review of the literature</article-title>. <source>Br J Nutr</source>
<year>2007</year>;<volume>97</volume>:<fpage>823</fpage>&#x02013;<lpage>831</lpage>.<pub-id pub-id-type="pmid">17408522</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0019">
<string-name>
<surname>van der Meij</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Langius</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Spreeuwenberg</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Slootmaker</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Paul</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Smit</surname>
<given-names>EF</given-names>
</string-name>, et al. <article-title>Oral nutritional supplements containing n&#x02010;3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT</article-title>. <source>Eur J Clin Nutr</source>
<year>2012</year>;<volume>66</volume>:<fpage>399</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">22234041</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0020">
<string-name>
<surname>Weed</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Ferguson</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Gaff</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Hustead</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Voss</surname>
<given-names>AC</given-names>
</string-name>. <article-title>Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein&#x02010; and energy&#x02010;dense nutritional supplement containing eicosapentaenoic acid</article-title>. <source>Head Neck</source>
<year>2011</year>;<volume>33</volume>:<fpage>1027</fpage>&#x02013;<lpage>1033</lpage>.<pub-id pub-id-type="pmid">20967868</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0021">
<string-name>
<surname>Wigmore</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Falconer</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Plester</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Tisdale</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>DC</given-names>
</string-name>, et al. <article-title>The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer</article-title>. <source>Nutrition</source>
<year>1996</year>;<volume>12</volume>:<fpage>S27</fpage>&#x02013;<lpage>S30</lpage>.<pub-id pub-id-type="pmid">8850216</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0022">
<string-name>
<surname>Meguro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barley</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>PW</given-names>
</string-name>. <article-title>Development and validation of an improved, COPD&#x02010;specific version of the St. George Respiratory Questionnaire</article-title>. <source>Chest</source>
<year>2007</year>;<volume>132</volume>:<fpage>456</fpage>&#x02013;<lpage>463</lpage>.<pub-id pub-id-type="pmid">17646240</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0023">
<string-name>
<surname>Stallberg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nokela</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ehrs</surname>
<given-names>PO</given-names>
</string-name>, <string-name>
<surname>Hjemdal</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jonsson</surname>
<given-names>EW</given-names>
</string-name>. <article-title>Validation of the clinical COPD Questionnaire (CCQ) in primary care</article-title>. <source>Health Qual Life Outcomes</source>
<year>2009</year>;<volume>7</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">19320988</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0024">
<string-name>
<surname>Jones</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Harding</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wiklund</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Kline</surname>
<given-names>LN</given-names>
</string-name>. <article-title>Development and first validation of the COPD Assessment Test</article-title>. <source>Eur Respir J</source>
<year>2009</year>;<volume>34</volume>:<fpage>648</fpage>&#x02013;<lpage>654</lpage>.<pub-id pub-id-type="pmid">19720809</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0025">
<string-name>
<surname>Wilson</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Rubenstein</surname>
<given-names>LZ</given-names>
</string-name>, <string-name>
<surname>Chibnall</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baxi</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Appetite assessment: simple appetite questionnaire predicts weight loss in community&#x02010;dwelling adults and nursing home residents</article-title>. <source>Am J Clin Nutr</source>
<year>2005</year>;<volume>82</volume>:<fpage>1074</fpage>&#x02013;<lpage>1081</lpage>.<pub-id pub-id-type="pmid">16280441</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0026">
<string-name>
<surname>Ribaudo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Cella</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Lloyd</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Tchekmedyian</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Von Roenn</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Re&#x02010;validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire</article-title>. <source>Qual Life Res</source>
<year>2000</year>;<volume>9</volume>:<fpage>1137</fpage>&#x02013;<lpage>1146</lpage>.<pub-id pub-id-type="pmid">11401046</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0027">
<article-title>ATS statement: guidelines for the six&#x02010;minute walk test</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2002</year>;<volume>166</volume>:<fpage>111</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">12091180</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0028">
<string-name>
<surname>Geleijnse</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Giltay</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Grobbee</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Donders</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials</article-title>. <source>J Hypertens</source>
<year>2002</year>;<volume>20</volume>:<fpage>1493</fpage>&#x02013;<lpage>1499</lpage>.<pub-id pub-id-type="pmid">12172309</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0029">
<string-name>
<surname>Chatila</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Thomashow</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Minai</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Criner</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Make</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Comorbidities in chronic obstructive pulmonary disease</article-title>. <source>Proc Am Thorac Soc</source>
<year>2008</year>;<volume>5</volume>:<fpage>549</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">18453370</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0030">
<string-name>
<surname>Allaire</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Couture</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Leclerc</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Charest</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Marin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lepine</surname>
<given-names>MC</given-names>
</string-name>, et al. <article-title>Randomized, crossover, head&#x02010;to&#x02010;head comparison of EPA and DHA supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA Study</article-title>. <source>Am J Clin Nutr</source>
<year>2016</year>.</mixed-citation></ref><ref id="jcsm12228-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0031">
<string-name>
<surname>Calder</surname>
<given-names>PC</given-names>
</string-name>. <article-title>Omega&#x02010;3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?</article-title>
<source>Br J Clin Pharmacol</source>
<year>2013</year>;<volume>75</volume>:<fpage>645</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">22765297</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0032">
<string-name>
<surname>Ries</surname>
<given-names>AL</given-names>
</string-name>. <article-title>Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale</article-title>. <source>COPD</source>
<year>2005</year>;<volume>2</volume>:<fpage>105</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">17136970</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0033">
<string-name>
<surname>Holland</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Rasekaba</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Naughton</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>CF</given-names>
</string-name>. <article-title>Updating the minimal important difference for six&#x02010;minute walk distance in patients with chronic obstructive pulmonary disease</article-title>. <source>Arch Phys Med Rehabil</source>
<year>2010</year>;<volume>91</volume>:<fpage>221</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">20159125</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0034">
<string-name>
<surname>Spruit</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Vercoulen</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Sprangers</surname>
<given-names>MAG</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EFM</given-names>
</string-name>. <article-title>FATIGUE consortium. Fatigue in COPD: an important yet ignored symptom</article-title>. <source>Lancet Respir Med</source>
<year>2017</year>; <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2213-2600(17)30158-3">https://doi.org/10.1016/S2213&#x02010;2600(17)30158&#x02010;3</ext-link>.</mixed-citation></ref><ref id="jcsm12228-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0035">
<string-name>
<surname>Jones</surname>
<given-names>PW</given-names>
</string-name>. <article-title>St. George's Respiratory Questionnaire: MCID</article-title>. <source>COPD</source>
<year>2005</year>;<volume>2</volume>:<fpage>75</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">17136966</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0036">
<string-name>
<surname>Curtis</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Deyo</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Hudson</surname>
<given-names>LD</given-names>
</string-name>. <article-title>Pulmonary rehabilitation in chronic respiratory insufficiency. 7. Health&#x02010;related quality of life among patients with chronic obstructive pulmonary disease</article-title>. <source>Thorax</source>
<year>1994</year>;<volume>49</volume>:<fpage>162</fpage>&#x02013;<lpage>170</lpage>.<pub-id pub-id-type="pmid">8128407</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0037">
<string-name>
<surname>Schols</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Slangen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Volovics</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EF</given-names>
</string-name>. <article-title>Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med</source>
<year>1998</year>;<volume>157</volume>:<fpage>1791</fpage>&#x02013;<lpage>1797</lpage>.<pub-id pub-id-type="pmid">9620907</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0038">
<string-name>
<surname>van de Bool</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rutten</surname>
<given-names>EPA</given-names>
</string-name>, <string-name>
<surname>van Helvoort</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Franssen</surname>
<given-names>FME</given-names>
</string-name>, <string-name>
<surname>Wouters</surname>
<given-names>EFM</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>AMWJ</given-names>
</string-name>. <article-title>A randomised clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD</article-title>. <source>J Cachexia Sarcopenia Muscle</source> Accepted April 2017.</mixed-citation></ref><ref id="jcsm12228-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0039">
<string-name>
<surname>Balk</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Lichtenstein</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kupelnick</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chew</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lau</surname>
<given-names>J</given-names>
</string-name>. <article-title>Effects of omega&#x02010;3 fatty acids on serum markers of cardiovascular disease risk: a systematic review</article-title>. <source>Atherosclerosis</source>
<year>2006</year>;<volume>189</volume>:<fpage>19</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">16530201</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0040">
<string-name>
<surname>Abeywardena</surname>
<given-names>MY</given-names>
</string-name>, <string-name>
<surname>Patten</surname>
<given-names>GS</given-names>
</string-name>. <article-title>Role of omega3 long&#x02010;chain polyunsaturated fatty acids in reducing cardio&#x02010;metabolic risk factors</article-title>. <source>Endocr Metab Immune Disord Drug Targets</source>
<year>2011</year>;<volume>11</volume>:<fpage>232</fpage>&#x02013;<lpage>246</lpage>.<pub-id pub-id-type="pmid">21831036</pub-id></mixed-citation></ref><ref id="jcsm12228-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jcsm12228-cit-0041">
<string-name>
<surname>von Haehling</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Morley</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Coats</surname>
<given-names>AJS</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015</article-title>. <source>J Cachexia Sarcopenia Muscle</source>
<year>2015</year>;<volume>6</volume>:<fpage>315</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">26672494</pub-id></mixed-citation></ref></ref-list></back></article>